A meta-analysis [78] of advanced NSCLC patients showed that 57% of EGFR mutant patients in tissue samples were ctDNA positive, while 43% were ctDNA negative, suggesting the limitations of EGFR–ctDNA testing. This evidence concerns the gene EGFR and non-small cell lung carcinoma.